Skip to main content

Advertisement

Open Peer Review Reports for: Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
22 Jul 2008 Submitted Original manuscript
8 Sep 2008 Reviewed Reviewer Report - Ker Yu
10 Sep 2008 Reviewed Reviewer Report - Robert Weiss
16 Sep 2008 Reviewed Reviewer Report - Hans Prenen
30 Sep 2008 Reviewed Reviewer Report - Sandrine Faivre
31 Oct 2008 Author responded Author comments - Roman Blaheta
Resubmission - Version 2
31 Oct 2008 Submitted Manuscript version 2
23 Nov 2008 Reviewed Reviewer Report - Hans Prenen
25 Nov 2008 Reviewed Reviewer Report - Ker Yu
9 Dec 2008 Reviewed Reviewer Report - Sandrine Faivre
15 Dec 2008 Reviewed Reviewer Report - Robert Weiss
24 Mar 2009 Author responded Author comments - Roman Blaheta
Resubmission - Version 3
24 Mar 2009 Submitted Manuscript version 3
23 Apr 2009 Reviewed Reviewer Report - Ker Yu
7 May 2009 Reviewed Reviewer Report - Robert Weiss
18 May 2009 Author responded Author comments - Roman Blaheta
Resubmission - Version 4
18 May 2009 Submitted Manuscript version 4
Publishing
27 May 2009 Editorially accepted
27 May 2009 Article published 10.1186/1471-2407-9-161

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement